

Pharmaceutically acceptable salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate and their use in therapy

The present invention relates to salts of an 8-oxoadenine derivative, pharmaceutical compositions containing them and their use in therapy.

5

Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate is specifically disclosed in Example 2-37 of published International Patent Application No. WO 2005/092893 as an immuno-modulating compound that acts via Toll-like Receptor 7 (TLR7).

10

In the formulation of drug substances, it is important for the drug substance (active compound) to be in a form in which it can be conveniently handled and processed. This is of importance, not only from the point of view of obtaining a commercially-viable manufacturing process for the drug substance itself, but also from the point of view of subsequent manufacture of pharmaceutical formulations comprising the active compound and suitable excipients. In this connection, the chemical stability and the physical stability of the active compound are important factors. The active compound, and formulations containing it, must be capable of being effectively stored over appreciable periods of time, without exhibiting any significant change in the physico-chemical characteristics (e.g. chemical composition, density, hygroscopicity and solubility) of the active compound.

20

Furthermore, if the active compound is to be incorporated into a formulation for pulmonary administration, e.g., via a dry powder inhaler such as the Turbuhaler® device, it is desirable if the active compound can be readily micronised to yield a powder with good flow properties and comprising a high fine particle fraction (i.e. a fraction in which the active compound particles have a mass median diameter (MMD) of less than or equal to 10 µm (micrometer)). Such a fraction is capable of being carried deep into the lungs leading to faster and increased absorption of the active compound.

25


The person skilled in the art will appreciate that, typically, if a drug substance can be readily obtained in a stable form, such as a stable crystalline form, advantages may be

30

provided, in terms of ease of handling, ease of preparation and extended shelf-life of suitable pharmaceutical formulations, and a more reliable solubility profile.

It has now surprisingly been found possible to prepare certain salts of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate having improved physico-chemical properties compared to the free base compound, which are capable of being formulated in a dry powder formulation for pulmonary administration.

The structure of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate is shown below:



Thus, in accordance with the present invention, there is provided a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate (hereinafter referred to as the “hydrochloride, hydrobromide or maleate salt”).

In another aspect, the invention provides a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate which exhibits the characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) shown in Table A, B or C respectively (see Example 4 hereinafter).

The invention also provides solvates (including hydrates) of the hydrochloride, hydrobromide or maleate salt. However, the hydrochloride, hydrobromide or maleate salt is preferably anhydrous, and is preferably in non-solvated form.

5 In an embodiment of the invention, the hydrochloride, hydrobromide or maleate salt or solvate thereof has crystalline properties and is preferably at least 50% crystalline, more preferably at least 60% crystalline, still more preferably at least 70% crystalline and most preferably at least 80% crystalline. Crystallinity can be estimated by conventional X-ray diffractometry techniques.

10

In another embodiment of the invention, the hydrochloride, hydrobromide or maleate salt or solvate thereof is from 50%, 60%, 70%, 80% or 90% to 95%, 96%, 97%, 98%, 99% or 100% crystalline.

15 The preparation of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate is described in published International Patent Application No. WO 2005/092893. The hydrochloride, hydrobromide and maleate salts (including solvated forms) of this compound can be prepared according to known techniques. However, it will be apparent to the person skilled in the art that there
20 will be other possible routes for making this compound and its salts.

The salts (including the solvated forms) according to the invention are useful as modulators of TLR7 activity and thus may administered to a mammal, including man, for the treatment of the following conditions or diseases:

- 25 1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema;
30 bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and

chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and
5 iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

2. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses,
10 and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian
15 syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;

3. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory
20 disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;

4. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-
25 vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

5. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;

6. other auto-immune and allergic disorders including rheumatoid arthritis, irritable
30 bowel syndrome, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic

thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome and Sazary syndrome;

7. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
8. infectious diseases: virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, candida, aspergillus, cryptococcal meningitis, pneumocystis carinii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.

Thus, the present invention provides a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt, for use in therapy.

In a further aspect, the present invention provides the use of a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt, in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the

disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

5

In particular, the salts (including the solvated forms) according to the invention may be used in the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis.

10 The invention therefore provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt.

15

The invention also provides a method of treating an airways disease, e.g. a reversible obstructive airways disease such as asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt.

20

The invention still further provides a method of treating, or reducing the risk of, a disease or condition comprising or arising from abnormal cell growth (e.g. a cancer), which method comprises administering to a patient in need thereof a therapeutically effective amount of a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt.

25

30 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the salt employed, the mode of administration, the treatment desired and the disorder indicated. For example, the daily dosage of the (solvated) hydrochloride, hydrobromide or

maleate salt, if inhaled, may be in the range from 0.05 micrograms per kilogram body weight ($\mu\text{g/kg}$) to 100 micrograms per kilogram body weight ($\mu\text{g/kg}$). Alternatively, if the (solvated) hydrochloride, hydrobromide or maleate salt is administered orally, then the daily dosage may be in the range from 0.01 micrograms per kilogram body weight ($\mu\text{g/kg}$) to 100 milligrams per kilogram body weight (mg/kg).

The hydrochloride, hydrobromide or maleate salt or solvate thereof according to the invention may be used on its own but will generally be administered in the form of a pharmaceutical composition in which the hydrochloride, hydrobromide or maleate salt or solvate thereof (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

Depending on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler[®]; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.

In an embodiment of the invention, the pharmaceutical composition is administered by inhalation (oral or nasal).

In a further embodiment, the pharmaceutical composition is administered by means of a dry powder inhaler (DPI).

The DPI may be "passive" or breath-actuated, or "active" where the powder is dispersed by some mechanism other than the patient's inhalation, for instance, an internal supply of compressed air. At present, three types of passive dry powder inhalers are available: single-dose, multiple unit dose or multidose (reservoir) inhalers. In single-dose devices, individual doses are provided, usually in gelatine capsules, and have to be loaded into the inhaler before use, examples of which include Spinhaler[®] (Aventis), Rotahaler[®] (GlaxoSmithKline), Aeroliser[™] (Novartis), Inhalator[®] (Boehringer) and Eclipse (Aventis) devices. Multiple unit dose inhalers contain a number of individually packaged doses, either as multiple gelatine capsules or in blisters, examples of which include Diskhaler[®] (GlaxoSmithKline), Diskus[®] (GlaxoSmithKline) and Aerohaler[®] (Boehringer) devices. In multidose devices, drug is stored in a bulk powder reservoir from which individual doses are metered, examples of which include Turbuhaler[®] (AstraZeneca), Easyhaler[®] (Orion), Novolizer[®] (ASTA Medica), Clickhaler[®] (Innovata Biomed) and Pulvinal[®] (Chiesi) devices.

An inhalable pharmaceutical composition or dry powder formulation for use in a DPI can be prepared by mixing finely divided active ingredient (having a mass median diameter generally equal to or less than 10 μm , preferably equal to or less than 5 μm) with a carrier substance, for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol.
5 Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. The powder mixture may then, as required, be dispensed into hard gelatine capsules, each containing the desired dose of the active ingredient.

10 Alternatively, an inhalable pharmaceutical composition may be prepared by processing a finely divided powder (e.g. consisting of finely divided active ingredient and finely divided carrier particles) into spheres that break up during the inhalation procedure. This spheronized powder is filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler[®] in which a dosing unit meters the desired dose which is then
15 inhaled by the patient.

Accordingly, the present invention also provides a dry powder inhaler, in particular a multiple unit dose dry powder inhaler, containing an inhalable pharmaceutical composition of the invention.

20

The hydrochloride, hydrobromide or maleate salt or solvate thereof according to the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.

25 The invention therefore further relates to combination therapies wherein a hydrochloride, hydrobromide or maleate salt or solvate thereof according to the invention, or a pharmaceutical composition comprising a hydrochloride, hydrobromide or maleate salt or solvate thereof according to the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of
30 one or more of the conditions listed.

FIG. 1 shows an X-ray powder diffraction pattern of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)-acetate monohydrochloride.

5 FIG. 2 shows an X-ray powder diffraction pattern of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)-acetate monohydrobromide.

FIG. 3 shows an X-ray powder diffraction pattern of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)-acetate dimaleate.

The present invention will now be further explained by reference to the following illustrative examples.

15

General Methods

¹H NMR spectra were recorded at 298K on a Varian Unity *Inova* 400 MHz (software : VNMR 6.1C and VNMRJ 1.1D; probe: Nalorac 5mm DG400-5AT) or a Varian *Mercury*-VX 300 MHz (software: VNMR 6.1C; probe: Varian 5mm AutoSW PFG) instrument. The
20 central peaks of acetone-*d*₆ or dimethylsulphoxide (DMSO)-*d*₆ were used as internal references.

The following method was used for LC/MS analysis:

MS Instrument:	Agilent 1100 series, equipped with APCI interface
25 LC instrument:	Agilent 1100 series, equipped with UV-detector VWD, autosampler ALS, binary pump and degasser
LC-column:	Chromolith Speed ROD, RP-C18, ø 4.6 x 50 mm
Eluant:	Solvent A: water + 0.1% trifluoroacetic acid (TFA); Solvent B: acetonitrile + 0.1% TFA
30 Conditions	LC: flow 2.5 ml/minute; 5 to 95% B in gradient; run time 3.6 minutes; UV 220 nm

MS: positive detection; capillary voltage 3 kV

Example 1

Preparation of hydrochloric acid salt of methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate (1:1 salt)

(a) Methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate (40 mg, 0.07mmol) was dissolved in ethyl acetate (5mL) and 3.28M HCl / ethanol solution (21 μ L, 0.07mmol) was added. The solvent was removed by evaporation and the residue was dried *in vacuo* to give methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate monohydrochloride as the final product.

(b) A 80mM solution of hydrochloric acid in methanol (65.0 μ l, 5.2 μ mol) was added to a solution of methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate (3.0 mg, 5.3 μ mol) dissolved in methanol (1.5 ml) at room temperature. The solution was shaken at 60°C for one hour, then cooled to 5°C. After 30 minutes, the solvent was left to slowly evaporate at 5°C, to give methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate monohydrochloride as the final product.

Further quantities of the monohydrochloride salt were prepared by the following method:

25

(c) A stoichiometric amount of a solution of hydrochloric acid in methanol (2.4 weight ratio, WR) was added to a suspension of methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]phenyl)acetate in methanol (4.0 WR) at 5°C. After stirring for 10 minutes, the white suspension had dissolved to give a clear solution. *tert*-Butyl methyl ether (5.1 WR) was added dropwise to the solution and following an addition of seed crystal of methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl]-

30

phenyl)acetate monohydrochloride prepared as described in (a) above, a white precipitate formed. After stirring for 5 minutes, *tert*-butyl methyl ether (11.2 WR) was added, and the suspension stirred for 1 hour at 5°C. The precipitate was filtered and washed with *tert*-butyl methyl ether (3.7 WR) to give methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate monohydrochloride as a solid (yield 90%).

Elemental Analysis

Element	C	H	N	Cl
Found ratio (wt%)	57.18	7.26	16.22	5.88
Theoretical ratio (wt%)	57.46	7.32	16.18	5.85

The stoichiometry, base to acid, of 1:1 was confirmed by NMR.

Example 2

Preparation of hydrobromic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate (1:1 salt)

(a) A 1.55M solution of hydrobromide in ethanol (34 μ l, 53 μ mol) was added to a solution of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate (30 mg, 0.053 mmol) in methanol (0.3 ml). The solution was dropped into *tert*-butyl methyl ether (0.9ml) at room temperature. The clear solution was left at -10°C for a week, after which time a crystalline substance precipitated. The crystalline material, methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate monohydrobromide, was filtered and dried.

Further quantities of the monohydrobromide salt were prepared by the following method:

(b) A stoichiometric amount of a solution of hydrobromic acid (aq., 48%) in methanol (0.8 WR) was added to a suspension of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-

dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate in methanol (11.9 WR) at room temperature. After stirring for 10 minutes, the white suspension had dissolved to give a clear solution. A seed crystal of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate monohydrobromide prepared as described in (a) above was added. *tert*-Butyl methyl ether (11.3 WR) was then added dropwise to the solution to give a white precipitate. The suspension was cooled to 3°C and stirred for 1 hour. The precipitate was filtered and washed with *tert*-butyl methyl ether (3.7 WR) to give methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate monohydrobromide as a solid (yield 87.7-89.4%).

The stoichiometry, base to acid, of 1:1 was confirmed by NMR.

Example 3

Preparation of maleic acid salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate (1:2 salt)

(a) A 27 mM solution of maleic acid in 1,4-dioxane (0.5 ml, 13.5 μ mol) was added to a solution of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate (4 mg, 7 μ mol) in 1,4-dioxane (0.75 ml) at room temperature and the mixture was left standing overnight. The next day, the solution was heated to 40°C and shaken for one hour, and thereafter allowed to cool to room temperature. The solvent was evaporated at room temperature to give methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate dimaleate as the final product.

Further quantities of the dimaleate salt were prepared by the following method:

(b) Maleic acid (0.9 g, 7.8 mmol) was added to a mixture of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}-

phenyl)acetate (2.2 g, 3.9 mmol) in methanol (20 ml) and isopropyl alcohol (20 ml) and the mixture was heated to 50°C until a clear solution was obtained. The solution was allowed to cool to room temperature and then seeded with a crystal of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}-phenyl)acetate dimaleate prepared as described in (a) above. After 16 hours the solid was
5 filtered and dried at 50°C under high vacuum for 72 hours. Yield 2.96g, 95%.

¹H NMR (DMSO-*d*₆); δ 9.88 (s, 1H), 7.32-7.22 (m, 4H), 6.43 (s, 2H), 6.11 (s, 4H), 4.12 (t, 2H), 3.95 (s, 2H), 3.71 (brs, 6H), 3.68 (s, 2H), 3.60 (s, 3H), 2.94-2.75 (m, 10H), 1.99-1.94 (m, 2H),
10 1.90-1.80 (m, 2H), 1.65-1.58 (m, 2H), 1.41-1.32 (m, 2H), 0.90 (t, 3H).

LC-MS m/z 570 APCI+ve

Elemental analysis

Element	C	H	N
Found ratio (wt%)	55.8	6.2	12.1
Theoretical ratio (wt%)	55.4	6.4	12.2

15 The stoichiometry, base to acid, of 1:2 was confirmed by NMR.

Example 4

X-Ray Powder Diffraction Analyses

20 General Procedures

X-ray powder diffraction (XRPD) analyses may be performed on samples prepared according to standard methods (see for example Giacovazzo *et al.*, eds., Fundamentals of Crystallography, Oxford University Press (1992); Jenkins & Snyder, eds., Introduction to X-Ray Powder Diffractometry, John Wiley & Sons, New York (1996); Bunn, ed.,
25 Chemical Crystallography, Clarendon Press, London (1948); and Klug & Alexander eds., X-ray Diffraction Procedures, John Wiley & Sons, New York (1974)).

X-ray powder diffraction patterns of the salts described in Examples 1 to 3 above (in anhydrous form) were obtained as described below:

A Bragg-Brentano parafocusing powder X-ray diffractometer using monochromatic $\text{CuK}\alpha$ radiation (45 kV and 40 mA) was used for the analyses. The primary optics contained soller slits and an automatic divergence slit. Flat samples were prepared on zero background plates that were rotated during the measurements. The secondary optics contained soller slits, an automatic anti scatter slit, a receiving slit and a monochromator. The diffracted signal was detected with a proportional xenon-filled detector. Diffraction patterns were collected between $2^\circ \leq 2\theta$ (theta) $\leq 40^\circ$ in a continuous scan mode with a step size of $0.016^\circ 2\theta$ at a rate of $4^\circ 2\theta$ per minute. Raw data were stored electronically. Evaluation was performed on raw or smoothed diffraction patterns.

A Panalytical X'pert PRO MPD θ - θ diffractometer in reflection mode was used for the above-mentioned measurements. A person skilled in the art can set up instrumental parameters for a powder X-ray diffractometer so that diffraction data comparable to the data presented can be collected. The results obtained are shown in FIG. 1, FIG.2 and FIG. 3. Tables A, B and C below each list the 2θ (2 theta) values (Accuracy: $\pm 0.1^\circ 2\theta$), d-spacings and the relative intensities of the peaks shown in the X-ray diffraction patterns of respectively Figures 1, 2 and 3.

Table A XRPD of Hydrochloride Salt					
2θ ($^\circ$)	d-spacing ($\text{\AA}$)	Relative Intensity (%)	2θ ($^\circ$)	d-spacing ($\text{\AA}$)	Relative Intensity (%)
4.6	19.2	100	16.9	5.2	21
9.2	9.7	7	17.6	5.0	15
10.1	8.8	3	19.2	4.6	8
11.3	7.8	5	20.2	4.4	22
12.1	7.3	6	21.7	4.1	22
13.2	6.7	4	22.1	4.0	7

Table A XRPD of Hydrochloride Salt					
2 θ (°)	d-spacing (Å)	Relative Intensity (%)	2 θ (°)	d-spacing (Å)	Relative Intensity (%)
13.7	6.5	10	22.9	3.9	4
16.2	5.5	6	24.1	3.7	22
16.5	5.4	8	27.1	3.3	6

Table B XRPD of Hydrobromide Salt					
2 θ (°)	d-spacing (Å)	Relative Intensity (%)	2 θ (°)	d-spacing (Å)	Relative Intensity (%)
5.1	17.2	100	20.7	4.3	45
9.7	9.1	10	21.0	4.2	52
10.2	8.6	16	21.3	4.2	73
10.5	8.4	6	22.2	4.0	21
10.8	8.2	12	22.5	4.0	26
13.3	6.7	16	22.9	3.9	10
15.1	5.9	19	23.2	3.8	10
15.9	5.6	25	24.0	3.7	13
16.8	5.3	14	24.5	3.6	56
17.1	5.2	52	24.9	3.6	14
17.7	5.0	16	25.7	3.5	14
17.9	5.0	36	26.1	3.4	16
18.0	4.9	15	26.3	3.4	13
18.4	4.8	13	27.3	3.3	9
18.7	4.7	22			

Table C XRPD of Maleate Salt					
2 θ (°)	d-spacing (Å)	Relative Intensity (%)	2 θ (°)	d-spacing (Å)	Relative Intensity (%)
5.0	17.7	19	17.9	5.0	32
9.3	9.5	86	18.1	4.9	62
9.8	9.1	33	18.5	4.8	16
9.9	8.9	15	19.4	4.6	15
11.5	7.7	24	19.7	4.5	48
11.8	7.5	27	19.9	4.5	30
12.1	7.3	26	20.7	4.3	16
12.6	7.0	17	20.9	4.3	26
13.9	6.4	40	22.1	4.0	32
14.9	5.9	73	22.7	3.9	16
15.6	5.7	15	22.9	3.9	39
15.9	5.6	12	24.3	3.7	100
16.3	5.4	13	24.9	3.6	88
16.7	5.3	16	26.5	3.4	30
17.3	5.1	32			

Example 5

Differential Scanning Calorimetry (DSC)

5

Using standard methods, for example those described in Höhne, G. W. H. et al (1996), Differential Scanning Calorimetry, Springer, Berlin, the calorimetric response of a test sample to increasing temperature was investigated using a TA Instruments Q1000 Modulated Temperature Differential Scanning Calorimeter (MTDSC) using a modulation of $\pm 0.50^\circ\text{C}$ in intervals of 40 seconds and a ramp rate of 5°C per minute. Approximately 1 to 5 mg of test sample was placed in aluminium cups with lids (no crimping) under a nitrogen atmosphere.

10

It is well known that the DSC onset and peak temperatures may vary due to the purity of the sample and instrumental parameters, especially the temperature scan rate. A person skilled in the art can use routine optimization/calibration to set up instrumental parameters for a differential scanning calorimeter so that data comparable to the data presented here can be collected.

The melting temperature for a typical sample of the anhydrous monohydrochloride salt obtained in Example 1(c) was found to be $144^{\circ}\text{C} \pm 3^{\circ}\text{C}$ (onset).

The melting temperature for a typical sample of the anhydrous monohydrobromide salt obtained in Example 2(b) was found to be $150^{\circ}\text{C} \pm 3^{\circ}\text{C}$ (onset).

The melting temperature for a typical sample of the anhydrous dimaleate salt obtained in Example 3(b) was found to be $150^{\circ}\text{C} \pm 3^{\circ}\text{C}$ (onset).

Example 6

Particle Size Reduction

Particle size reduction using a 2" Spiral Jet Mill (SJM) was carried out on the following three test substances: the monohydrochloride salt according to Example 1 (invention salt), the dimaleate salt according to Example 3 (invention salt) and the free base compound, methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate (comparison compound).

A sieved batch of test substance was fed into the jet mill chamber, via a venturi feed system, by a vibratory feeder. Micronisation was achieved by particle collisions brought about by compressed gas (nitrogen) forced through angled nozzles in the jet mill chamber. Particles of different sizes develop different speeds and momentum and as the particle size is reduced the particles spiral towards the centre of the jet mill and exit via an exhaust into a collection bin. The process parameters that control the particle size, in addition to the

inherent properties of the compound to be micronised, are the feed rate, grinding pressure and venturi pressure and these are summarised in Table I following.

Table I

Test Substance	Amount processed (g)	Yield (%)	Feed rate	Venturi Pressure (bar)	Grind Pressure (bar)
Comparison compound	1.7	1.7	Constant flow	5 (4)	2 (1)
Dimalcate salt	2.0	48	Constant flow	5	2
Monohydrochloride salt	37	85	Constant flow	5	1

5

Due to build-up of the comparison compound in the exhaust, the mill became plugged. Lowering of the grind/venturi pressures from 2/5 bar to 1/4 bar had no significant beneficial effect in this respect. Thus, particle size reduction of the comparison compound was aborted after only 1.7g of the intended 7g had been loaded.

10

By contrast, the monohydrochloride and dimalcate salts were readily micronised and there was no significant build-up or blocking of the mill during processing.

Example 7

15 Measurement of Fine Particle Fraction (FPF)

Procedure

Measurement of FPF, starting from substance as received, was carried out according to the following series of steps:

- 20 1. Particle size reduction (micronisation) of received substance.
2. Particle size measurement (after size reduction) using laser diffraction instrument.
3. Manual sample loading.

4. Deaggregation of powder and collection of aerosol in cascade impactor.
5. Quantification using high pressure liquid chromatography (HPLC) and calculation of FPF.

- 5 Three substances were tested: the monohydrochloride salt according to Example 1 (invention salt), the monohydrobromide salt according to Example 2 (invention salt) and the free base compound, methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate (comparison compound).

10

Particle size reduction

Particle size reduction (micronisation) was performed in a jet mill in which pressurised gas was used to make the substance particles collide at high speed in order to effect particle size reduction.

15

Particle size measurement

Particle size measurements were performed with laser diffraction using a Malvern Scirocco instrument. The results obtained are presented in Table 1 following.

20 Table 1

Test substance	Pressure (bar)	d(0.1) (µm)	d(0.5) (µm)	d(0.9) (µm)
Comparison compound	4	0.6	1.7	4.1
Monohydrochloride (invention)	1.5	0.9	1.8	3.5
Monohydrobromide (invention)	1.5	0.8	1.9	4.1

Sample loading

Doses of 1-2 mg were weighed manually (without scraping) into the cavities of a prototype inhaler (see below). Two experiments were run for each test substance and two doses were used in each experiment and, thus, in total, four doses of each test substance were used in the experiments. The samples were dried in nitrogen gas atmosphere overnight before conducting the experiments.

Experimental set-up and deaggregation of powder

The Next Generation Impactor, NGI, was used for the fine particle assessment. This cascade impactor is described in pharmacopoeias such as USP (general chapter <601> AERSOLS, NASAL SPRAYS, METERED-DOSE INHALERS, AND DRY POWDER INHALERS, apparatus 5) and Eur. Pharmacopoeia (5.8 section 2.9.18 PREPARATIONS FOR INHALATION: AERODYNAMIC ASSESSMENT OF FINE PARTICLES, apparatus E), where there is a detailed description about how to set up, operate and calibrate the impactor for use at different flow rates. Two NGI impactors were used, one per experiment.

A simple prototype inhaler was used for the tests, consisting of an L-shaped cylindrical channel, comprising a vertical component and a horizontal component. The prototype inhaler was fitted via an USP-inlet to the NGI impactor. The micronised powder was transferred through the vertical channel into the bend of the prototype inhaler, (i.e. the bend of the L-shaped channel).

Each dose of 1-2 mg of powder was drawn with an airflow of 60 liters/min for 2 seconds (measured at the entrance of the induction port), entraining the powder located in the bend, and the aerosol thereafter moved through the horizontal component of the channel, through a spiral mouthpiece and into the NGI impactor. The drug powders were collected in the induction port and in eight cups (see references given above).

The withdrawal and collection of the drug powders was performed in an isolator (glove) box with a relative humidity level below 2%.

HPLC analysis

The drug powder contents of the induction port and in the eight cups were then quantified using High Pressure Liquid Chromatography methodology as described in Table 2.

5 Table 2

Parameter	Test substance		
	Comparison cpd.	Monohydrochloride	Monohydrobromide
Column	Thermo Electron Hypersil Gold 50 mm X 3 mm. 3µm particles	Symmetry C18 150 mm X 3mm. 3.5µm particles	Symmetry C18 150 mm X 3mm. 3.5µm particles
Column temperature (°C)	60	20	40
Flow (ml/min)	1.0	0.64	0.64
Mobile phase A	0.1% ammonium acetate in water	0.02% trifluoro- acetic acid in water	0.02% trifluoro- acetic acid in water
Mobile phase B	0.1 % ammonium acetate in water/acetonitrile (10/90%)	0.02% trifluoro- acetic acid in acetonitrile	0.02% trifluoro- acetic acid in acetonitrile
Composition	Isocratic, A/B : 60/40%	Isocratic, A/B : 81/19%	Isocratic, A/B : 81/19%
Injection volume (µl)	20.0	75	75
Detector wavelength (nm)	283	244	244

Calculation

Key data used for the calculations of FPF as obtained from the HPLC analyses are presented in Table 3. The FPF's, as defined in the pharmacopoeia references above, were calculated.

5

Table 3

Data	Test substance					
	Comparison cpd.		Mono-hydrochloride		Mono-hydrobromide	
	NGI1	NGI2	NGI1	NGI2	NGI1	NGI2
Delivered amount (µg)	720	1396	1257	992	1123	975
Collected in stage 3-8 (<4.5 µm) (µg)	131	178	383	392	319	414
Amount particles < 5µm, extrapolated (µg)	139	189	393	402	332	427
FPF (%<5µm/delivered dose)	19.3	13.6	31.3	40.6	29.6	43.8
FPF (%<5µm/delivered dose), Average over NGI's	16.4		35.9		36.7	

CLAIMS

1. A hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]-
5 methyl}phenyl)acetate or a solvate of the salt.
2. Methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate monohydrochloride.
- 10 3. Methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate monohydrobromide.
4. Methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate dimaleate.
15
5. A pharmaceutical composition comprising a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
20
6. A pharmaceutical composition according to claim 5 which is in the form of a dry powder formulation for use in inhalation therapy.
7. A dry powder inhaler containing a pharmaceutical composition as claimed in claim 6.
25
8. A process for the preparation of a pharmaceutical composition as claimed in claim 5 which comprises mixing a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a solvate of the salt with a pharmaceutically
30 acceptable adjuvant, diluent or carrier.

9. The salt according to any one of Claims 1 to 4 or the pharmaceutical composition according to Claim 5 or 6 for use in therapy.
10. Use of the salt according to any one of Claims 1 to 4 or the pharmaceutical composition according to Claim 5 or 6 in the manufacture of a medicament for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.
11. A hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-
10 amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate or a solvate of the salt for use in the treatment of a reversible obstructive airways disease.
12. The use of a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3-
15 {[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino)methyl}phenyl)acetate or a solvate of the salt in the manufacture of a medicament for the treatment of a reversible obstructive airways disease.